Cover Image
市場調查報告書

整合素β1:開發中產品分析

Integrin Beta 1 (Fibronectin Receptor Subunit Beta or Glycoprotein Iia or VLA 4 Subunit Beta or CD29 or ITGB1) - Pipeline Review, H1 2017

出版商 Global Markets Direct 商品編碼 367836
出版日期 內容資訊 英文 49 Pages
訂單完成後即時交付
價格
Back to Top
整合素β1:開發中產品分析 Integrin Beta 1 (Fibronectin Receptor Subunit Beta or Glycoprotein Iia or VLA 4 Subunit Beta or CD29 or ITGB1) - Pipeline Review, H1 2017
出版日期: 2017年06月13日 內容資訊: 英文 49 Pages
簡介

本報告提供以整合素β1為標的治療藥之開發平台現狀及最新更新的各開發階段比較分析,提供您附最新的新聞和發表之企業和研究機關正在開發的治療藥,治療藥評估,後期階段及中止的計劃等相關資訊。

簡介

  • 調查範圍

整合素β1 概要

治療藥的開發

  • 開發中的產品:各開發階段
  • 開發中的產品:各治療領域
  • 開發中的產品:不同症狀

開發中產品概況

  • 後期階段的產品
  • 初期階段的產品

企業開發中的產品

大學/機關開發中的產品

治療藥的評估

  • 單劑/並用治療藥的情況
  • 各作用機制
  • 各給藥途徑
  • 各分子類型

治療藥開發企業

  • Clanotech AB
  • Valeant Pharmaceuticals International, Inc.

藥物簡介

暫停中的計劃

開發中止的產品

主要消息及新聞稿

附錄

圖表

本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。

目錄
Product Code: GMDHC0808TDB

Summary

According to the recently published report 'Integrin Beta 1 - Pipeline Review, H1 2017'; Integrin Beta 1 (Fibronectin Receptor Subunit Beta or Glycoprotein Iia or VLA 4 Subunit Beta or CD29 or ITGB1) pipeline Target constitutes close to 16 molecules. Out of which approximately 14 molecules are developed by companies and remaining by the universities/institutes.

Integrin Beta 1 (Fibronectin Receptor Subunit Beta or Glycoprotein Iia or VLA 4 Subunit Beta or CD29 or ITGB1) - Integrin beta-1 also known as CD29 is a protein encoded by the ITGB1 gene. It is involved in up-regulation of the activity of kinases such as PKC via binding to KRT1. It plays a mechanistic adhesive role during telophase. Integrin alpha-3/beta-1 provides a docking site for FAP at invadopodia plasma membranes in a collagen-dependent manner and participates in the adhesion, formation of invadopodia and matrix degradation processes, promoting cell invasion.

The report 'Integrin Beta 1 - Pipeline Review, H1 2017' outlays comprehensive information on the Integrin Beta 1 (Fibronectin Receptor Subunit Beta or Glycoprotein Iia or VLA 4 Subunit Beta or CD29 or ITGB1) targeted therapeutics, complete with analysis by indications, stage of development, mechanism of action (MoA), route of administration (RoA) and molecule type; that are being developed by Companies / Universities.

It also reviewsalso reviews key players involved in Integrin Beta 1 (Fibronectin Receptor Subunit Beta or Glycoprotein Iia or VLA 4 Subunit Beta or CD29 or ITGB1) targeted therapeutics development with respective active and dormant or discontinued projects. Currently, The molecules developed by companies in Phase II, Phase I, Preclinical and Discovery stages are 1, 1, 8 and 4 respectively. Similarly, the universities portfolio in Preclinical stages comprises 2 molecules, respectively. Report covers products from therapy areas Musculoskeletal Disorders, Genetic Disorders, Ophthalmology, Cardiovascular, Dermatology, Immunology, Oncology and Respiratory which include indications Muscular Dystrophy, Duchenne Muscular Dystrophy, Wet (Neovascular / Exudative) Macular Degeneration, Arterial Thrombosis, Breast Cancer, Cardiovascular Disease, Prostate Cancer, Pulmonary Fibrosis, Rheumatoid Arthritis and Scar.

Note: Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

Scope

  • The report provides a snapshot of the global therapeutic landscape for Integrin Beta 1 (Fibronectin Receptor Subunit Beta or Glycoprotein Iia or VLA 4 Subunit Beta or CD29 or ITGB1)
  • The report reviews Integrin Beta 1 (Fibronectin Receptor Subunit Beta or Glycoprotein Iia or VLA 4 Subunit Beta or CD29 or ITGB1) targeted therapeutics under development by companies and universities/research institutes based on information derived from company and industry-specific sources
  • The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages
  • The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities
  • The report reviews key players involved in Integrin Beta 1 (Fibronectin Receptor Subunit Beta or Glycoprotein Iia or VLA 4 Subunit Beta or CD29 or ITGB1) targeted therapeutics and enlists all their major and minor projects
  • The report assesses Integrin Beta 1 (Fibronectin Receptor Subunit Beta or Glycoprotein Iia or VLA 4 Subunit Beta or CD29 or ITGB1) targeted therapeutics based on mechanism of action (MoA), route of administration (RoA) and molecule type
  • The report summarizes all the dormant and discontinued pipeline projects
  • The report reviews latest news and deals related to Integrin Beta 1 (Fibronectin Receptor Subunit Beta or Glycoprotein Iia or VLA 4 Subunit Beta or CD29 or ITGB1) targeted therapeutics

Reasons to buy

  • Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies
  • Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
  • Identify and understand the targeted therapy areas and indications for
  • Integrin Beta 1 (Fibronectin Receptor Subunit Beta or Glycoprotein Iia or VLA 4 Subunit Beta or CD29 or ITGB1)
  • Identify the use of drugs for target identification and drug repurposing
  • Identify potential new clients or partners in the target demographic
  • Develop strategic initiatives by understanding the focus areas of leading companies
  • Plan mergers and acquisitions effectively by identifying key players and it's most promising pipeline therapeutics
  • Devise corrective measures for pipeline projects by understanding Integrin Beta 1 (Fibronectin Receptor Subunit Beta or Glycoprotein Iia or VLA 4 Subunit Beta or CD29 or ITGB1) development landscape
  • Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope

Table of Contents

  • Table of Contents
    • List of Tables
    • List of Figures
  • Introduction
    • Global Markets Direct Report Coverage
  • Integrin Beta 1 (Fibronectin Receptor Subunit Beta or Glycoprotein Iia or VLA 4 Subunit Beta or CD29 or ITGB1) - Overview
    • Integrin Beta 1 (Fibronectin Receptor Subunit Beta or Glycoprotein Iia or VLA 4 Subunit Beta or CD29 or ITGB1) - Therapeutics Development
    • Products under Development by Stage of Development
    • Products under Development by Therapy Area
    • Products under Development by Indication
    • Products under Development by Companies
    • Products under Development by Universities/Institutes
  • Integrin Beta 1 (Fibronectin Receptor Subunit Beta or Glycoprotein Iia or VLA 4 Subunit Beta or CD29 or ITGB1) - Therapeutics Assessment
    • Assessment by Mechanism of Action
    • Assessment by Route of Administration
    • Assessment by Molecule Type
  • Integrin Beta 1 (Fibronectin Receptor Subunit Beta or Glycoprotein Iia or VLA 4 Subunit Beta or CD29 or ITGB1) - Companies Involved in Therapeutics Development
    • Clanotech AB
    • Strykagen Corp
    • Valeant Pharmaceuticals International Inc
  • Integrin Beta 1 (Fibronectin Receptor Subunit Beta or Glycoprotein Iia or VLA 4 Subunit Beta or CD29 or ITGB1) - Drug Profiles
    • AXT-108 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • C-16Y - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • CLT-28643 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • SAL-021 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • Small Molecule to Inhibit Integrin alpha 2 beta 1 for Arterial Thrombosis - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • Small Molecules to Antagonize Integrin Alpha V and Beta 1 for Cardiovascular Disease - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • Stryka-232 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • Stryka-234 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • Stryka-425 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • Stryka-516 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • Stryka-516s - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • Stryka-533 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • Stryka-969 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • Stryka-978 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • StrykaPro-1 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • Synthetic Peptides to Antagonize Alpha5Beta1 Integrin for Breast and Prostate Cancer - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
  • Integrin Beta 1 (Fibronectin Receptor Subunit Beta or Glycoprotein Iia or VLA 4 Subunit Beta or CD29 or ITGB1) - Dormant Products
  • Integrin Beta 1 (Fibronectin Receptor Subunit Beta or Glycoprotein Iia or VLA 4 Subunit Beta or CD29 or ITGB1) - Discontinued Products
  • Integrin Beta 1 (Fibronectin Receptor Subunit Beta or Glycoprotein Iia or VLA 4 Subunit Beta or CD29 or ITGB1) - Product Development Milestones
    • Featured News & Press Releases
      • Jun 15, 2015: Clanotech's lead compound in development, CLT-28643, has recently been granted a European Patent by the European Patent Office
      • May 12, 2015: Clanotech to present CLT-28643 in the treatment of eye disease at BioTrinity 2015 on 13 May 2015
      • Mar 27, 2015: Clanotech granted Orphan Drug Designation by the U.S. FDA
      • Oct 20, 2014: Clanotech receives orphan drug designation in the EU
      • Dec 23, 2013: Santarus Initiates Phase IIa Study with SAN-300 in Patients with Active Rheumatoid Arthritis
      • Oct 25, 2013: Santarus Announces Presentation of SAN-300 Phase I Data at 2013 American College of Rheumatology Annual Meeting
      • Mar 10, 2011: Santarus Initiates Phase I Clinical Study With SAN-300
  • Appendix
    • Methodology
    • Coverage
    • Secondary Research
    • Primary Research
    • Expert Panel Validation
    • Contact Us
  • Disclaimer

List of Tables

  • Number of Products under Development by Stage of Development, H1 2017
  • Number of Products under Development by Therapy Areas, H1 2017
  • Number of Products under Development by Indication, H1 2017
  • Number of Products under Development by Companies, H1 2017
  • Products under Development by Companies, H1 2017
  • Number of Products under Investigation by Universities/Institutes, H1 2017
  • Products under Investigation by Universities/Institutes, H1 2017
  • Number of Products by Stage and Mechanism of Actions, H1 2017
  • Number of Products by Stage and Route of Administration, H1 2017
  • Number of Products by Stage and Molecule Type, H1 2017
  • Pipeline by Clanotech AB, H1 2017
  • Pipeline by Strykagen Corp, H1 2017
  • Pipeline by Valeant Pharmaceuticals International Inc, H1 2017
  • Dormant Products, H1 2017
  • Dormant Products, H1 2017 (Contd..1), H1 2017
  • Dormant Products, H1 2017 (Contd..2), H1 2017
  • Discontinued Products, H1 2017

List of Figures

  • Number of Products under Development by Stage of Development, H1 2017
  • Number of Products under Development by Therapy Areas, H1 2017
  • Number of Products under Development by Top 10 Indications, H1 2017
  • Number of Products by Mechanism of Actions, H1 2017
  • Number of Products by Stage and Mechanism of Actions, H1 2017
  • Number of Products by Routes of Administration, H1 2017
  • Number of Products by Stage and Routes of Administration, H1 2017
  • Number of Products by Molecule Types, H1 2017
  • Number of Products by Stage and Molecule Types, H1 2017
Back to Top